280 related articles for article (PubMed ID: 10855790)
1. Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors.
Schlaeppi JM; Wood JM
Cancer Metastasis Rev; 1999; 18(4):473-81. PubMed ID: 10855790
[TBL] [Abstract][Full Text] [Related]
2. The pivotal role of VEGF in tumor angiogenesis: molecular facts and therapeutic opportunities.
Siemeister G; Martiny-Baron G; Marmé D
Cancer Metastasis Rev; 1998 Jun; 17(2):241-8. PubMed ID: 9770121
[No Abstract] [Full Text] [Related]
3. The role of vascular endothelial growth factor in angiogenesis.
Ferrara N; Gerber HP
Acta Haematol; 2001; 106(4):148-56. PubMed ID: 11815711
[TBL] [Abstract][Full Text] [Related]
4. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine.
Brown LF; Detmar M; Claffey K; Nagy JA; Feng D; Dvorak AM; Dvorak HF
EXS; 1997; 79():233-69. PubMed ID: 9002222
[TBL] [Abstract][Full Text] [Related]
5. VEGF receptor signaling in tumor angiogenesis.
McMahon G
Oncologist; 2000; 5 Suppl 1():3-10. PubMed ID: 10804084
[TBL] [Abstract][Full Text] [Related]
6. Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics.
Zhu Z; Bohlen P; Witte L
Curr Cancer Drug Targets; 2002 Jun; 2(2):135-56. PubMed ID: 12188915
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor.
Zhu Z; Witte L
Invest New Drugs; 1999; 17(3):195-212. PubMed ID: 10665474
[TBL] [Abstract][Full Text] [Related]
8. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
Yano S; Herbst RS; Shinohara H; Knighton B; Bucana CD; Killion JJ; Wood J; Fidler IJ
Clin Cancer Res; 2000 Mar; 6(3):957-65. PubMed ID: 10741721
[TBL] [Abstract][Full Text] [Related]
9. [Anti-angiogenic reagents].
Shibuya M
Tanpakushitsu Kakusan Koso; 2000 Apr; 45(6 Suppl):1182-7. PubMed ID: 10771693
[No Abstract] [Full Text] [Related]
10. Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation.
Verheul HM; Hoekman K; Jorna AS; Smit EF; Pinedo HM
Oncologist; 2000; 5 Suppl 1():45-50. PubMed ID: 10804091
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Wood JM
Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS
J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897
[TBL] [Abstract][Full Text] [Related]
13. The role of vascular endothelial growth factor (VEGF) in AIDS-related Kaposi's sarcoma.
Arastéh K; Hannah A
Oncologist; 2000; 5 Suppl 1():28-31. PubMed ID: 10804088
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications.
Ellis LM; Takahashi Y; Liu W; Shaheen RM
Oncologist; 2000; 5 Suppl 1():11-5. PubMed ID: 10804085
[TBL] [Abstract][Full Text] [Related]
15. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
Petit AM; Rak J; Hung MC; Rockwell P; Goldstein N; Fendly B; Kerbel RS
Am J Pathol; 1997 Dec; 151(6):1523-30. PubMed ID: 9403702
[TBL] [Abstract][Full Text] [Related]
16. Two independent mechanisms essential for tumor angiogenesis: inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway.
Siemeister G; Schirner M; Weindel K; Reusch P; Menrad A; Marmé D; Martiny-Baron G
Cancer Res; 1999 Jul; 59(13):3185-91. PubMed ID: 10397264
[TBL] [Abstract][Full Text] [Related]
17. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice.
Brekken RA; Overholser JP; Stastny VA; Waltenberger J; Minna JD; Thorpe PE
Cancer Res; 2000 Sep; 60(18):5117-24. PubMed ID: 11016638
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft.
Stefanik DF; Fellows WK; Rizkalla LR; Rizkalla WM; Stefanik PP; Deleo AB; Welch WC
J Neurooncol; 2001 Nov; 55(2):91-100. PubMed ID: 11817706
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor and its receptors.
Klagsbrun M; D'Amore PA
Cytokine Growth Factor Rev; 1996 Oct; 7(3):259-70. PubMed ID: 8971481
[TBL] [Abstract][Full Text] [Related]
20. Vascular permeability factor/vascular endothelial growth factor-mediated signaling in mouse mesentery vascular endothelium.
Mukhopadhyay D; Nagy JA; Manseau EJ; Dvorak HF
Cancer Res; 1998 Mar; 58(6):1278-84. PubMed ID: 9515816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
